5th Apr 2007 12:00
PuriCore (LSE:PURI), the life sciences company focused on thedevelopment and commercialization of its novel, safe antimicrobialtechnology, today announced that it has received 510(k) clearance fromthe US Food and Drug Administration (FDA), allowing it to market itsproprietary Sterilox Endoscopy High-Level Disinfectant System as amedical device in the US. The Sterilox System produces a highlyeffective and safe high-level disinfectant solution that is indicatedfor use in reprocessing and disinfecting heat-sensitive medicalinstruments, including endoscopes, between patient procedures. £ The Sterilox Endoscopy System is based on existing patented andpatent-pending PuriCore technology and products that are currentlymarketed in Europe (primarily in the UK). It produces principallyhypochlorous acid, the natural antimicrobial produced by the humanbody to fight pathogens, from the electrolysis of a saline solution.Sterilox Solutions are completely non-toxic and are of no risk topatients, healthcare professionals, or the environment. £ "This is a big step in bringing Sterilox to the US endoscopymarket, which is the largest in the world," said Greg Bosch, PuriCoreCEO. "We are now developing our commercialization plan and, upon thecompletion of post-clearance testing, we anticipate installing ourfirst US beta sites for Sterilox Endoscopy Systems by year end." £ About PuriCore £ PuriCore (London Stock Exchange:PURI) is a life sciences companyfocused on developing and commercializing proprietary products thatsafely, effectively, and naturally kill contagious pathogens.PuriCore's technology mimics the human body's production of thenatural antimicrobial hypochlorous acid, which is highly effective inkilling bacteria, viruses, and fungal spores. PuriCore's technologyprovides a potential solution in a broad range of markets that dependupon controlling contamination, including food safety, medical devicedisinfection, wound management, and hospitality. Deploying hypocholousacid solutions as soaks, sprays, mists and in other forms, PuriCore'stechnology is designed to limit the spread of infectious disease,including major public health threats of Tuberculosis, MRSA, E.coli,norovirus, avian influenza, HIV, polio virus, Helicobater pylori, andLegionella. £ To receive additional information on PuriCore or its SteriloxEndoscopy division, please visit our web site at www.puricore.com,which does not form part of this press release. Copyright Business Wire 2007Related Shares:
RLM.L